JPWO2020252264A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020252264A5 JPWO2020252264A5 JP2021573353A JP2021573353A JPWO2020252264A5 JP WO2020252264 A5 JPWO2020252264 A5 JP WO2020252264A5 JP 2021573353 A JP2021573353 A JP 2021573353A JP 2021573353 A JP2021573353 A JP 2021573353A JP WO2020252264 A5 JPWO2020252264 A5 JP WO2020252264A5
- Authority
- JP
- Japan
- Prior art keywords
- prodrug
- moiety
- seq
- antibody
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000651 prodrug Substances 0.000 claims description 86
- 229940002612 prodrug Drugs 0.000 claims description 86
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 52
- 102000003812 Interleukin-15 Human genes 0.000 claims description 40
- 108090000172 Interleukin-15 Proteins 0.000 claims description 40
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 34
- 230000000873 masking effect Effects 0.000 claims description 32
- 102220629430 Very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase 1_E64Q_mutation Human genes 0.000 claims description 22
- 230000035772 mutation Effects 0.000 claims description 18
- 102200155472 rs397507510 Human genes 0.000 claims description 18
- 229920001184 polypeptide Polymers 0.000 claims description 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 14
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 12
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 12
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 12
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 210000004027 cell Anatomy 0.000 claims description 10
- 102100026802 72 kDa type IV collagenase Human genes 0.000 claims description 8
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 102220578647 Chorion-specific transcription factor GCMb_N65D_mutation Human genes 0.000 claims description 6
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 claims description 6
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 claims description 6
- 108010091175 Matriptase Proteins 0.000 claims description 6
- 102100037942 Suppressor of tumorigenicity 14 protein Human genes 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 230000004071 biological effect Effects 0.000 claims description 6
- 102000040430 polynucleotide Human genes 0.000 claims description 6
- 108091033319 polynucleotide Proteins 0.000 claims description 6
- 239000002157 polynucleotide Substances 0.000 claims description 6
- 208000035473 Communicable disease Diseases 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 108010088751 Albumins Proteins 0.000 claims description 4
- 102000009027 Albumins Human genes 0.000 claims description 4
- 102220556497 Deubiquitinase MYSM1_I67D_mutation Human genes 0.000 claims description 4
- 101001055157 Homo sapiens Interleukin-15 Proteins 0.000 claims description 4
- 102220514958 Vacuolar protein sorting-associated protein 4B_L66D_mutation Human genes 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 102000056003 human IL15 Human genes 0.000 claims description 4
- 210000000987 immune system Anatomy 0.000 claims description 4
- 230000004936 stimulating effect Effects 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims description 4
- 102220537135 Alpha-parvin_L66E_mutation Human genes 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 101710151806 72 kDa type IV collagenase Proteins 0.000 claims description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 2
- 102220578645 Chorion-specific transcription factor GCMb_N65A_mutation Human genes 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 102220531889 Glucose-fructose oxidoreductase domain-containing protein 1_K10A_mutation Human genes 0.000 claims description 2
- 102220532061 Glucose-fructose oxidoreductase domain-containing protein 1_K11A_mutation Human genes 0.000 claims description 2
- 102100029880 Glycodelin Human genes 0.000 claims description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 2
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 2
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 2
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 2
- 102000017578 LAG3 Human genes 0.000 claims description 2
- 101150030213 Lag3 gene Proteins 0.000 claims description 2
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims description 2
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims description 2
- 208000009018 Medullary thyroid cancer Diseases 0.000 claims description 2
- 108010006035 Metalloproteases Proteins 0.000 claims description 2
- 102000005741 Metalloproteases Human genes 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 102220490907 Olfactomedin-like protein 2A_N72A_mutation Human genes 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 102000035195 Peptidases Human genes 0.000 claims description 2
- 108091005804 Peptidases Proteins 0.000 claims description 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 239000004365 Protease Substances 0.000 claims description 2
- 102220645736 RNA-binding protein 7_L69E_mutation Human genes 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 102220608445 Suppressor of cytokine signaling 2_I68E_mutation Human genes 0.000 claims description 2
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 2
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 2
- 102220607778 TYRO protein tyrosine kinase-binding protein_E64A_mutation Human genes 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 210000004899 c-terminal region Anatomy 0.000 claims description 2
- 102220406091 c.188T>A Human genes 0.000 claims description 2
- 238000003776 cleavage reaction Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 102200042996 rs1057521927 Human genes 0.000 claims description 2
- 102220053806 rs121918461 Human genes 0.000 claims description 2
- 102220311640 rs1382779104 Human genes 0.000 claims description 2
- 102200042487 rs141568342 Human genes 0.000 claims description 2
- 102200054160 rs28941775 Human genes 0.000 claims description 2
- 102220075004 rs758871507 Human genes 0.000 claims description 2
- 230000007017 scission Effects 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 239000013598 vector Substances 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962860635P | 2019-06-12 | 2019-06-12 | |
| US62/860,635 | 2019-06-12 | ||
| US201962888444P | 2019-08-17 | 2019-08-17 | |
| US62/888,444 | 2019-08-17 | ||
| US201962891190P | 2019-08-23 | 2019-08-23 | |
| US62/891,190 | 2019-08-23 | ||
| US202062959973P | 2020-01-11 | 2020-01-11 | |
| US62/959,973 | 2020-01-11 | ||
| US202063029473P | 2020-05-23 | 2020-05-23 | |
| US63/029,473 | 2020-05-23 | ||
| PCT/US2020/037439 WO2020252264A1 (en) | 2019-06-12 | 2020-06-12 | Novel il-15 prodrugs and methods of use thereof |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022536898A JP2022536898A (ja) | 2022-08-22 |
| JPWO2020252264A5 true JPWO2020252264A5 (https=) | 2023-05-31 |
| JP2022536898A5 JP2022536898A5 (https=) | 2023-05-31 |
| JP7676329B2 JP7676329B2 (ja) | 2025-05-14 |
Family
ID=71995031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021573353A Active JP7676329B2 (ja) | 2019-06-12 | 2020-06-12 | 新規ｉｌ－１５プロドラッグおよびその使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11845801B2 (https=) |
| EP (1) | EP3983432A1 (https=) |
| JP (1) | JP7676329B2 (https=) |
| KR (1) | KR20220020879A (https=) |
| CN (1) | CN114341189A (https=) |
| AU (2) | AU2020291012B2 (https=) |
| CA (1) | CA3141626A1 (https=) |
| WO (1) | WO2020252264A1 (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| US11084863B2 (en) | 2017-06-30 | 2021-08-10 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains |
| CA3097625A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof |
| KR20210003813A (ko) | 2018-04-18 | 2021-01-12 | 젠코어 인코포레이티드 | IL-15/IL-15Rα Fc-융합 단백질 및 LAG-3 항원 결합 도메인을 함유하는 LAG-3 표적화 이종이량체 융합 단백질 |
| AU2019271148B9 (en) | 2018-05-14 | 2025-05-29 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
| CA3100005A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| US12459980B2 (en) | 2018-07-25 | 2025-11-04 | AskGene Pharma, Inc. | IL-21 prodrugs and methods of use thereof |
| CN120463822A (zh) | 2018-09-27 | 2025-08-12 | 西里欧发展公司 | 掩蔽型细胞因子多肽 |
| CN113438961A (zh) | 2018-12-20 | 2021-09-24 | Xencor股份有限公司 | 含有IL-15/IL-15Rα和NKG2D抗原结合结构域的靶向异二聚体Fc融合蛋白 |
| KR20220023988A (ko) | 2019-05-14 | 2022-03-03 | 웨어울프 세라퓨틱스, 인크. | 분리 모이어티 및 이의 사용 방법 |
| US20220356221A1 (en) * | 2019-09-28 | 2022-11-10 | AskGene Pharma, Inc. | Cytokine prodrugs and dual-prodrugs |
| TW202128757A (zh) | 2019-10-11 | 2021-08-01 | 美商建南德克公司 | 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白 |
| BR112022009110A2 (pt) | 2019-11-14 | 2022-07-26 | Werewolf Therapeutics Inc | Polipeptídeos de citocina ativáveis e métodos de uso destes |
| JP2023502712A (ja) * | 2019-11-21 | 2023-01-25 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） | 抗ｐｄ－１／ｉｌ－１５免疫サイトカインによる新しいｐｄ－１標的免疫療法 |
| CN115315434A (zh) * | 2019-12-05 | 2022-11-08 | 免疫靶向有限公司 | 白细胞介素15融合蛋白和前药及其组合物和方法 |
| MX2022007202A (es) * | 2019-12-13 | 2022-10-07 | Cugene Inc | Fármacos bioactivables a base de citocinas y metodos de uso de los mismos. |
| WO2021142471A1 (en) | 2020-01-11 | 2021-07-15 | AskGene Pharma, Inc. | Novel masked cytokines and methods of use thereof |
| IL296911A (en) * | 2020-04-01 | 2022-12-01 | Xilio Dev Inc | Masked il-15 cytokines and their cleavage products |
| BR112022019841A2 (pt) | 2020-04-09 | 2022-12-06 | Cytomx Therapeutics Inc | Composições contendo anticorpos ativáveis |
| AU2021254283B2 (en) | 2020-04-10 | 2025-12-11 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| CN115916809A (zh) * | 2020-05-18 | 2023-04-04 | 江苏先声药业有限公司 | 人il-15突变体及其用途 |
| AU2021345852A1 (en) * | 2020-09-16 | 2023-05-25 | Beone Medicines I Gmbh | Interleukin 15 constructs and methods of use |
| WO2022115865A2 (en) | 2020-11-25 | 2022-06-02 | Xilio Development, Inc. | Tumor-specific cleavable linkers |
| AU2022206475A1 (en) * | 2021-01-11 | 2023-08-17 | Adimab, Llc | Variant ch3 domains engineered for preferential ch3 heterodimerization, multi-specific antibodies comprising the same, and methods of making thereof |
| EP4284819A1 (en) * | 2021-02-01 | 2023-12-06 | Askgene Pharma, Inc. | Chimeric molecules comprising an il-10 or tgf-beta agonist polypeptide |
| IL304916A (en) * | 2021-02-05 | 2023-10-01 | Salubris Biotherapeutics Inc | Il-15 fusion proteins and methods of making and using same |
| JP2024511387A (ja) * | 2021-03-16 | 2024-03-13 | シートムエックス セラピューティクス，インコーポレイテッド | マスクした活性化可能サイトカイン構成体ならびに関連する組成物及び方法 |
| CN116655771A (zh) * | 2021-05-28 | 2023-08-29 | 苏州复融生物技术有限公司 | 一种新型白介素15突变体多肽的开发及其应用 |
| KR20240055714A (ko) * | 2021-07-09 | 2024-04-29 | 레전드 바이오테크 아일랜드 리미티드 | 돌연변이 il-15 조성물 및 이의 방법 |
| WO2023280287A1 (en) * | 2021-07-09 | 2023-01-12 | Nanjing Legend Biotech Co., Ltd. | Interleukin-15 variants and uses thereof |
| CA3227386A1 (en) * | 2021-07-28 | 2023-02-02 | Jianing Huang | Interleukin-2 muteins, fusion proteins, pharmaceutical compositions, and therapeutic applications |
| WO2023010031A1 (en) * | 2021-07-28 | 2023-02-02 | Genentech, Inc. | Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of blood cancers |
| WO2023161853A1 (en) | 2022-02-23 | 2023-08-31 | Bright Peak Therapeutics Ag | Activatable il-18 polypeptides |
| CN117088975B (zh) * | 2022-05-11 | 2024-06-25 | 东莞市朋志生物科技有限公司 | 抗白蛋白抗体、检测白蛋白的试剂和试剂盒 |
| WO2024031036A2 (en) * | 2022-08-05 | 2024-02-08 | Staidson Biopharma Inc. | Il-15 prodrug and uses thereof |
| CN116854821A (zh) * | 2022-08-15 | 2023-10-10 | 海徕科(北京)生物技术有限公司 | IL-15突变体-Fc/IL-15Rα亚基-Fc异源二聚体及其用途 |
| WO2024083953A1 (en) * | 2022-10-18 | 2024-04-25 | Tubulis Gmbh | Novel anti-tpbg antibody and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof |
| WO2024137136A1 (en) * | 2022-12-22 | 2024-06-27 | University Of Houston System | Inhibitors of il-15 and their use in treating or preventing sepsis, severe sepsis and septic shock |
| WO2024150175A1 (en) | 2023-01-11 | 2024-07-18 | Bright Peak Therapeutics Ag | Conditionally activated proteins and methods of use |
| US20240417436A1 (en) | 2023-01-11 | 2024-12-19 | Bright Peak Therapeutics Ag | Conditionally activated immunocytokines and methods of use |
| WO2025041101A1 (en) | 2023-08-23 | 2025-02-27 | Bright Peak Therapeutics Ag | Activatable il-18 immunocytokines and uses thereof |
| WO2025180355A1 (zh) * | 2024-02-27 | 2025-09-04 | 江苏奥赛康生物医药有限公司 | Il-15前药与免疫检查点抑制剂的组合 |
Family Cites Families (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5229109A (en) | 1992-04-14 | 1993-07-20 | Board Of Regents, The University Of Texas System | Low toxicity interleukin-2 analogues for use in immunotherapy |
| US7008624B1 (en) * | 1995-02-22 | 2006-03-07 | Immunex Corporation | Antagonists of interleukin-15 |
| JP4213224B2 (ja) | 1997-05-02 | 2009-01-21 | ジェネンテック，インコーポレーテッド | ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法 |
| EP1489100B1 (en) | 1997-12-08 | 2016-06-15 | Merck Patent GmbH | Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation |
| US6955807B1 (en) | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| IL148079A0 (en) | 1999-08-24 | 2002-09-12 | Medarex Inc | Human ctla-4 antibodies and compositions containing the same |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| EP1261376A1 (en) | 2000-01-27 | 2002-12-04 | Genetics Institute, LLC | Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof |
| DE10045592A1 (de) | 2000-09-15 | 2002-03-28 | Klaus Pfizenmaier | Ein Antikörper-TNF-TNF Inhibitor Fusionsprotein (TNF-Selektokin) als zielspezifisches Prozytokin zur Tumortherapie |
| US6942853B2 (en) | 2001-01-09 | 2005-09-13 | Queen Mary And Westfield College | Latent fusion protein |
| US7371371B2 (en) | 2001-08-13 | 2008-05-13 | University Of Southern California | Interleukin-2 mutants with reduced toxicity |
| IL160358A0 (en) * | 2001-08-23 | 2004-07-25 | Genmab As | Human antibodies specific for interleukin 15 (il-15) |
| NZ567242A (en) | 2001-10-04 | 2009-11-27 | Genetics Inst Llc | Use of an IL-21/IL-21R agonist for modulating interleukin-21 receptor activity and treating cancer |
| ES2629395T3 (es) | 2001-10-04 | 2017-08-09 | Genetics Institute, Llc | Métodos y composiciones para modular la actividad de la interleucina-21 |
| US8809504B2 (en) | 2002-09-03 | 2014-08-19 | Vit Lauermann | Inhibitor which is deactivatable by a reagent produced by a target cell |
| US20060236411A1 (en) | 2002-10-14 | 2006-10-19 | Ingeborg Dreher | Antagonists il-15 |
| WO2005007121A2 (en) | 2003-07-18 | 2005-01-27 | Massachusetts Institute Of Technology | Mutant interleukin-2(il-2) polypeptides |
| US20080069791A1 (en) | 2003-12-29 | 2008-03-20 | Universitaetsklinikum Muenster | Means for stimulation and activation of hair growth by il-15 |
| AU2005203962C1 (en) | 2004-01-05 | 2012-11-08 | Antisoma Research Limited | Interleukin-12 targeted to oncofoetal fibronectin |
| EP1718670B1 (en) | 2004-02-27 | 2011-07-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Il-15 binding site for il 15-ralpha and specific il-15 mutants having agonist/antagonist activity |
| BRPI0508470A (pt) | 2004-03-05 | 2007-07-31 | Chiron Corp | sistema de teste in vitro para prever toleráncia do paciente aos agentes terapêuticos |
| EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| CA2656700A1 (en) | 2006-07-06 | 2008-01-10 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Compositions and methods for enhancing the efficacy of il-2 mediated immune responses |
| CA2671665A1 (en) | 2006-12-21 | 2008-06-26 | Novo-Nordisk A/S | Interleukin-21 variants with altered binding to the il-21 receptor |
| CA2697032C (en) | 2007-08-22 | 2021-09-14 | The Regents Of The University Of California | Activatable binding polypeptides and methods of identification and use thereof |
| WO2009061853A2 (en) | 2007-11-05 | 2009-05-14 | Massachusetts Institute Of Technology | Mutant interleukin-2 (il-2) polypeptides |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| MY153074A (en) | 2008-08-14 | 2014-12-31 | Teva Pharmaceuticals Australia Pty Ltd | Anti-il-12/11-23 antibodies |
| NZ592420A (en) | 2008-10-02 | 2012-12-21 | Emergent Product Dev Seattle | Cd86 antagonist multi-target binding proteins |
| MX2011007647A (es) | 2009-01-21 | 2011-09-01 | Amgen Inc | Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes. |
| JP5861223B2 (ja) | 2009-02-23 | 2016-02-16 | サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. | プロタンパク質およびその使用方法 |
| EP2553101A4 (en) | 2010-04-02 | 2013-09-04 | Univ Rochester | PROTEASE-ACTIVATED CYTOKINES |
| WO2011127324A2 (en) | 2010-04-08 | 2011-10-13 | JN Biosciences, LLC | Antibodies to cd122 |
| WO2012061536A2 (en) | 2010-11-02 | 2012-05-10 | The Trustees Of Columbia University In The City Of New York | Methods for treating hair loss disorders |
| CU23923B1 (es) | 2010-11-12 | 2013-07-31 | Ct De Inmunología Molecular | Polipéptidos derivados de la il-2 con actividad agonista |
| ES2866674T3 (es) | 2010-11-12 | 2021-10-19 | Nektar Therapeutics | Conjugados de una fracción de IL-2 y un polímero |
| US9428567B2 (en) | 2010-12-22 | 2016-08-30 | The Board Of Trustees Of The Leland Stanford Junior University | Antagonists of interleukin-2 receptor |
| HRP20200470T1 (hr) | 2011-01-18 | 2020-10-02 | Bioniz, Llc | Pripravci za modulaciju aktivnosti gama-c-citokina |
| HUE029139T2 (hu) | 2011-02-10 | 2017-02-28 | Roche Glycart Ag | Mutáns interleukin-2 polipeptidek |
| RS56793B1 (sr) | 2011-03-02 | 2018-04-30 | Roche Glycart Ag | Cea antitela |
| GB201103955D0 (en) | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| US8841418B2 (en) | 2011-07-01 | 2014-09-23 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to TIM3 |
| CA2876285A1 (en) | 2012-08-08 | 2014-02-13 | Roche Glycart Ag | Interleukin-10 fusion proteins and uses thereof |
| NZ630790A (en) * | 2012-10-24 | 2016-11-25 | Admune Therapeutics Llc | Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes |
| CA2904969C (en) | 2013-03-13 | 2025-06-17 | Imaginab, Inc. | DIFFERENTIATION CLUSTER ANTIGEN-BINDING GENETIC CONSTRUCTIONS 8 |
| EP2970486B1 (en) | 2013-03-15 | 2018-05-16 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| WO2015066279A2 (en) | 2013-10-30 | 2015-05-07 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
| RU2689717C2 (ru) | 2014-01-08 | 2019-05-28 | Шанхай Хэнжуй Фармасьютикал Ко., Лтд. | Гетеродимерный белок il-15 и его применения |
| WO2015110930A1 (en) | 2014-01-24 | 2015-07-30 | Pfizer Inc. | Modified interleukin 21 receptor proteins |
| AR099625A1 (es) | 2014-03-21 | 2016-08-03 | Lilly Co Eli | Anticuerpos de il-21 |
| HUE051676T2 (hu) | 2014-04-08 | 2021-03-29 | Boston Pharmaceuticals Inc | Il-21-re specifikus kötõ molekulák és alkalmazásaik |
| EP2963057A1 (en) | 2014-07-02 | 2016-01-06 | Calypso Biotech SA | Antibodies to IL-15 |
| GB2538666A (en) | 2014-07-21 | 2016-11-23 | Delinia Inc | Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases |
| CN104403004B (zh) | 2014-11-24 | 2017-10-13 | 苏州丁孚靶点生物技术有限公司 | 抗体‑干扰素异二聚体的制备和用途 |
| US20160176969A1 (en) | 2014-11-26 | 2016-06-23 | Xencor, Inc. | Heterodimeric antibodies including binding to cd8 |
| EP3226848A4 (en) | 2014-12-03 | 2019-04-03 | Phio Pharmaceuticals Corp. | METHOD FOR TREATING ALOPECIA AREATA USING GENE MODULATION APPARATUS |
| JO3575B1 (ar) | 2015-01-09 | 2020-07-05 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
| EP3244907B1 (en) | 2015-01-13 | 2020-02-19 | City of Hope | Ctla4-binding protein peptide-linker masks |
| US20160362469A1 (en) | 2015-06-12 | 2016-12-15 | Tianxin Wang | Methods for protein modification in pharmaceutical applications |
| CN112574316A (zh) * | 2015-07-02 | 2021-03-30 | 博际生物医药科技(杭州)有限公司 | 用于肿瘤靶向治疗的白细胞介素-15融合蛋白 |
| EP3350205A1 (en) | 2015-09-16 | 2018-07-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Specific interleukin-15 (il-15) antagonist polypeptide and uses thereof for the treatment of inflammatory and auto-immune diseases |
| US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| CR20180453A (es) * | 2016-03-22 | 2018-12-05 | Hoffmann La Roche | Moleculas biespecíficas de células t activadas por proteasas |
| EP3458485B1 (en) | 2016-05-19 | 2021-12-29 | The General Hospital Corporation | Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| US11617799B2 (en) | 2016-06-27 | 2023-04-04 | Tagworks Pharmaceuticals B.V. | Cleavable tetrazine used in bio-orthogonal drug activation |
| KR101928981B1 (ko) | 2016-09-02 | 2018-12-13 | 고려대학교 산학협력단 | 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 IL-21 (heterodimeric Fc-fused IL-21) 및 이를 포함하는 약제학적 조성물 |
| CN110214147A (zh) | 2016-10-14 | 2019-09-06 | Xencor股份有限公司 | IL15/IL15Rα异源二聚体FC-融合蛋白 |
| WO2018097308A1 (ja) | 2016-11-28 | 2018-05-31 | 中外製薬株式会社 | リガンド結合活性が調整可能なリガンド結合分子 |
| SI3558369T1 (sl) | 2016-12-21 | 2025-06-30 | Cephalon Llc | Protitelesa, ki se specifično vežejo na človeški il-15, in njihova uporaba |
| CN107082812B (zh) | 2017-03-29 | 2018-11-13 | 上海科医联创生物科技有限公司 | 一种恢复衰竭性免疫细胞功能的融合蛋白及其应用 |
| AU2018250641B2 (en) * | 2017-04-11 | 2025-03-13 | Inhibrx Biosciences, Inc. | Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same |
| CN111050803A (zh) | 2017-06-20 | 2020-04-21 | 德克萨斯大学系统董事会 | 用于治疗癌症的干扰素前药 |
| WO2019173832A2 (en) | 2018-03-09 | 2019-09-12 | AskGene Pharma, Inc. | Novel cytokine prodrugs |
| CN110396133B (zh) | 2018-04-25 | 2021-07-23 | 免疫靶向有限公司 | 一种以白介素12为活性成分的融合蛋白型药物前体 |
| CA3100005A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| AU2019271148B9 (en) | 2018-05-14 | 2025-05-29 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
| TWI705820B (zh) | 2018-06-22 | 2020-10-01 | 美商美國禮來大藥廠 | Gip/glp1促效劑組合物 |
| EP3810624A4 (en) | 2018-06-22 | 2022-07-06 | Cugene Inc. | Cytokine-based bioactivatable drugs and methods of uses thereof |
| US12459980B2 (en) | 2018-07-25 | 2025-11-04 | AskGene Pharma, Inc. | IL-21 prodrugs and methods of use thereof |
| CN120463822A (zh) | 2018-09-27 | 2025-08-12 | 西里欧发展公司 | 掩蔽型细胞因子多肽 |
| WO2020214690A1 (en) | 2019-04-15 | 2020-10-22 | Qwixel Therapeutics | Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer |
| EP3976182A4 (en) | 2019-05-03 | 2023-01-18 | Bioniz, LLC | MODULATION OF THE EFFECTS OF GAMMA CYTOKINE SIGNALING FOR THE TREATMENT OF ALOPECIA AND ALOPECIA-ASSOCIATED DISORDERS |
| AU2020287373B2 (en) | 2019-06-05 | 2026-01-29 | Asher Biotherapeutics, Inc. | Fusions of mutant interleukin-2 polypeptides with antigen binding molecules for modulating immune cell function |
| CA3148505A1 (en) | 2019-08-12 | 2021-02-18 | AskGene Pharma, Inc. | Novel il-2 fusion molecules |
| US20220289822A1 (en) | 2019-08-21 | 2022-09-15 | AskGene Pharma, Inc. | Novel il-21 prodrugs and methods of use thereof |
| US20220356221A1 (en) | 2019-09-28 | 2022-11-10 | AskGene Pharma, Inc. | Cytokine prodrugs and dual-prodrugs |
| WO2021142471A1 (en) | 2020-01-11 | 2021-07-15 | AskGene Pharma, Inc. | Novel masked cytokines and methods of use thereof |
| EP4277707A1 (en) | 2021-01-14 | 2023-11-22 | Askgene Pharma, Inc. | Interferon prodrugs and methods of making and using the same |
| WO2022159395A1 (en) | 2021-01-20 | 2022-07-28 | Viking Therapeutics, Inc. | Compositions and methods for the treatment of metabolic and liver disorders |
| EP4284819A1 (en) | 2021-02-01 | 2023-12-06 | Askgene Pharma, Inc. | Chimeric molecules comprising an il-10 or tgf-beta agonist polypeptide |
| WO2022178103A1 (en) | 2021-02-17 | 2022-08-25 | AskGene Pharma, Inc. | Il-2 receptor beta subunit mutants |
| MX2024003236A (es) | 2021-09-15 | 2024-06-19 | Viking Therapeutics Inc | Composiciones y metodos para el tratamiento de trastornos metabolicos y hepaticos. |
-
2020
- 2020-06-12 KR KR1020227000221A patent/KR20220020879A/ko active Pending
- 2020-06-12 EP EP20753488.4A patent/EP3983432A1/en active Pending
- 2020-06-12 JP JP2021573353A patent/JP7676329B2/ja active Active
- 2020-06-12 AU AU2020291012A patent/AU2020291012B2/en active Active
- 2020-06-12 CA CA3141626A patent/CA3141626A1/en active Pending
- 2020-06-12 CN CN202080042103.8A patent/CN114341189A/zh active Pending
- 2020-06-12 US US16/900,677 patent/US11845801B2/en active Active
- 2020-06-12 WO PCT/US2020/037439 patent/WO2020252264A1/en not_active Ceased
-
2023
- 2023-10-19 US US18/490,268 patent/US20240067739A1/en active Pending
-
2025
- 2025-12-19 AU AU2025283612A patent/AU2025283612A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020252264A5 (https=) | ||
| JP7820448B2 (ja) | 新規のサイトカインプロドラッグ | |
| US12447208B2 (en) | Anti-CTLA4 monoclonal antibody or its antigen binding fragments, pharmaceutical compositions and uses | |
| CN112534052B (zh) | 全新il-21前药及使用方法 | |
| JP5938473B2 (ja) | 多価抗原結合Ｆｖ分子 | |
| KR20220020879A (ko) | 새로운 il-15 프로드럭 및 이를 사용하는 방법 | |
| CN115605504A (zh) | 新型il-21前药及其使用方法 | |
| JP2021526820A (ja) | 癌治療のための抗ｏｘＭＩＦ／抗ＣＤ３抗体 | |
| CN113412281B (zh) | Btn3a结合蛋白及其用途 | |
| CA3145387A1 (en) | Fusion proteins comprising a ligand-receptor pair and a biologically functional protein | |
| US20230272110A1 (en) | Antibodies that bind psma and gamma-delta t cell receptors | |
| US20240218065A1 (en) | Multispecific antigen-binding protein and use thereof | |
| JP2023159379A (ja) | Ｐｄ－１とｖｅｇｆを標的とした四価二重特異性抗体、その製造方法および用途 | |
| WO2022081794A1 (en) | Shielded biologics with masking domains to shield antigen binding capability of biologics and uses thereof | |
| CN115175938A (zh) | 制导和导航控制(gnc)抗体样蛋白及其制备和使用方法 | |
| TW202334204A (zh) | 條件性活化之抗原結合多肽複合物及其使用方法 | |
| US20250188166A1 (en) | Il-18 polypeptides fused to immune cell antigen specific binding polypeptides and uses thereof | |
| US12590159B2 (en) | Compositions targeting epidermal growth factor receptor and methods for making and using the same | |
| AU2020397229A1 (en) | Anti-oxMIF/anti-CD3 bispecific antibody constructs | |
| JP2023547662A (ja) | Ｃｌｄｎ６及びｃｄ３に選択的に結合するポリペプチド構築物 | |
| CA3252786A1 (en) | PROPROTEINS OF MULTISPECIFIC BONDING MOLECULES AND THEIR USES | |
| KR20250035049A (ko) | 인터루킨-2 프로프로테인 및 이의 용도 | |
| WO2022127066A1 (zh) | 一种特异性中和辅助性T细胞TGF-β信号的双特异性抗体、其药物组合及其用途 | |
| CN116348493A (zh) | 靶向PD-L1和TGF-β的双功能分子 | |
| US20250282874A1 (en) | Bifunctional protein, and preparation thereof and use thereof |